BioPharma Resources

Drug Trial Radar · NCT04317833

A Study of SSS17 in Healthy Subjects

A Single Dose Escalation Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of SSS17 in Chinese Healthy Subject

Last checked: Nov 19, 2026Latest source record: Mar 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

65

Planned (sponsor's estimate)

Start

May 1, 2020

Primary completion

Jun 30, 2021

Study completion Dec 31, 2021

Sponsor

Sponsor type
Industry
First posted
Mar 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human, Phase 1, single-center, randomized, single-blind, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, PD of SSS17 following oral administration in healthy subjects. Approximately 65 subjects (53 receiving active drug and 12 receiving placebo) will participate in this study.

Conditions

  • Anemia in Chronic Kidney Diseases

Interventions

  • SSS17Drug

    SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.

  • PlaceboDrug

    matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AEsTime frame: up to Day14 or 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Public Health Clinical Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.